Overview
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
Last reviewed: September 2022
We reviewed the evidence and found nothing new that affects the recommendations in this guidance. See the review decision for more details.
Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.
Diagnostics guidance 24 has been migrated to HealthTech guidance 413.
Guidance development process
How we develop diagnostics guidance
This guidance was previously called ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing.